Trials / Recruiting
RecruitingNCT06031441
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
A Phase I, Open-Label, Multicenter, Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 250 (estimated)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a first-in-human Phase I, open-label, dose-escalation and expansion study designed to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamic, and preliminary anti-tumor activity of RO7566802 as a single agent and in combination with atezolizumab in participants with locally advanced, recurrent, or metastatic incurable solid tumor malignancies. Participants will be enrolled in 2 stages: dose escalation and expansion.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RO7566802 | RO7566802 solution for infusion will be administered as specified in each treatment arm. |
| DRUG | Atezolizumab | Atezolizumab solution for infusion will be administered as specified in each treatment arm. |
Timeline
- Start date
- 2023-11-27
- Primary completion
- 2027-12-31
- Completion
- 2027-12-31
- First posted
- 2023-09-11
- Last updated
- 2026-04-03
Locations
18 sites across 5 countries: United States, Australia, Canada, Singapore, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06031441. Inclusion in this directory is not an endorsement.